PharmaTelevision - KaloBios: The Strategy of an Antibody-Based Company

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: KaloBios: The Strategy of an Antibody-Based Company

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview, Fintan Walton talks to Dave Pritchard, CEO of KaloBios Pharmaceuticals, about this antibody-based company, its platform technology and its research programmes. Dave discusses KaloBios’ financing through funding rounds, and its 2007 licensing deal with Novartis. He talks about KaloBios’ plans to raise more money through further partnering, and how the company has also been recently approached by strategic investors, leading to the possibility of an unusual corporate round of funding. Dave also touches on similarities between KaloBios and his last antibody company, Rinat Neuroscience, which was acquired by Pfizer for US$500 M, and mentions the possibility of KaloBios being similarly acquired.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

KaloBios Pharmaceuticals's platform technology and its research programmes

Fintan Walton:

Welcome to PharmaVentures Business Review brought to you by PharmaTelevision the world's first on demand pharmaceutical television channel. We are here in San Francisco recording a series of interviews at the annual JP Morgan Conference. This conference was originally run by the famous Hambrecht and Quist Bank and is one of the oldest events in biotechnology. Today thousands to send from around the US but also from around the world into San Francisco to do financial deals and recently it's also become an important partnering event. I hope you'll enjoy the series of interviews we've done from some of the key companies attending this conference.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here in San Francisco. On this show I have Dave Pritchard, who is CEO of KaloBios a local company here in Palo Alto, welcome to the show Dave.

Dave Pritchard:

Thanks for inviting me.

Fintan Walton:

Dave, tell us about KaloBios because you are obviously an antibody based company but what's different about KaloBios from all the other antibody based companies?

Dave Pritchard:

So KaloBios has a kind of unique platform technology that we make human antibodies we would argue are the best antibodies for chronic long-term treatment in broad patient populations and in addition we have now two programs in Phase II studies in fact this year will be doing six Phase II's to really expand and understand there what those drugs can do.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaTelevision. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan (US) and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Dave Pritchard

CEO

Dave Pritchard was appointed as President and CEO of KaloBios in October 2006. He joined KaloBios with more than 25 years of experience in general management, business development and financial management within the biopharmaceutical industry. Most recently he held the position of CBO at Rinat Neuroscience, where he managed the negotiations on the acquisition of Rinat by Pfizer in 2006, for a reported US$500 M. Before that that he was CFO at Matrix Pharmaceutical, and managed the sale of the company to Chiron (now Novartis) in 2002.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialization.

KaloBios Pharmaceuticals

KaloBios is a privately held biopharmaceutical company that uses its proprietary technologies to develop human antibody therapeutics. It currently has two programmes entering Phase I/II studies; KB-001 is an anti-infective for Pseudomonas aeruginosa infections to be tested in patients with cystic fibrosis and ventilator-associated pneumonia (VAP), and KB002 is an anti-inflammatory entering studies for rheumatoid arthritis and asthma. The company's technology, termed 'Humaneering', offers advantages over other methods of antibody development in terms of speed, cost, versatility and nearness to human germline sequence. KaloBios focuses on developing antibodies from the Humaneering stage to the early clinical stage, at which time it plans to partner them.